{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:05:35Z","timestamp":1789995935745,"version":"4.0.1"},"reference-count":29,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Background and Clinical Significance: Heart failure with reduced ejection fraction (HFrEF) is highly prevalent among patients with end-stage kidney disease (ESKD) undergoing maintenance hemodialysis (MHD) and is associated with poor clinical outcomes. Sacubitril\/valsartan (SV) is a cornerstone therapy for HFrEF; however, its use in dialysis patients remains limited due to safety concerns and lack of robust evidence. This case series describes the clinical response and safety of SV in patients with HFrEF receiving MHD; Case Presentation: Four male patients with HFrEF undergoing MHD were treated with SV and followed for 12 months. Baseline evaluation showed a left ventricular ejection fraction (LVEF) of 35.5%, left ventricular end-systolic volume (LVESV) of 118.5 mL, left ventricular end-diastolic volume (LVEDV) of 185.7 mL, pulmonary artery systolic pressure (PASP) of 52.7 mmHg, and NT-proBNP levels above 35,000 pg\/mL in all patients. After 12 months of SV therapy, LVEF improved to 53.7%, corresponding to a 51.4% relative increase from baseline. Reverse cardiac remodeling was observed, with LVESV decreasing to 58.2 mL and LVEDV to 110 mL, together with reductions in left ventricular dimensions. PASP decreased to 32 mmHg, and NT-proBNP levels declined to 7261.7 pg\/mL. Blood pressure improved, serum potassium remained stable at 4.95 mmol\/L, and no severe hyperkalemia, intradialytic hypotension, post-dialysis hypotension, or heart failure-related hospitalization occurred; Conclusions: In this case series, SV was associated with improved cardiac function, reverse remodeling, pulmonary pressure reduction, and an acceptable safety profile in patients with HFrEF undergoing MHD. These findings suggest a potential therapeutic role for SV in selected dialysis patients and support further investigation.<\/jats:p>","DOI":"10.3390\/reports9030291","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:31:13Z","timestamp":1788251473000},"page":"291","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sacubitril\/Valsartan in Patients with HFrEF Undergoing Maintenance Hemodialysis, Evidence of Cardiac Reverse Remodeling During 12-Month Follow-Up: Case Series"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-3971","authenticated-orcid":false,"given":"Sonila","family":"Mocka","sequence":"first","affiliation":[{"name":"Nephrology and Dialysis Unit, Department of Internal Medicine, San Paolo Hospital, Via Genova 30, 17100 Savona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Baccino","sequence":"additional","affiliation":[{"name":"Cardiolody and Cardiovascular Intensive Care Unit, Department of Emergency Medicine, San Paolo Hospital, 17100 Savona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ledio","family":"Shurdi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Vivantes Humboldt-Klinikum, 13509 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cornara","sequence":"additional","affiliation":[{"name":"Cardiolody and Cardiovascular Intensive Care Unit, Department of Emergency Medicine, San Paolo Hospital, 17100 Savona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ferraro","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Department of Internal Medicine, San Paolo Hospital, Via Genova 30, 17100 Savona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"sfag036","DOI":"10.1093\/ckj\/sfag036","article-title":"The ERA Registry Annual Report 2023: Epidemiology of Kidney Replacement Therapy in Europe, with a focus on age comparisons","volume":"19","author":"Hoekstra","year":"2026","journal-title":"Clin. Kidney J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"iii28","DOI":"10.1093\/ndt\/gfy174","article-title":"Cardiovascular disease in dialysis patients","volume":"33","author":"Cozzolino","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","article-title":"Heart failure in chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"House","year":"2019","journal-title":"Kidney Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e003648","DOI":"10.1161\/JAHA.116.003648","article-title":"Diagnosis and Management of Cardiovascular Disease in Advanced and End-Stage Renal Disease","volume":"5","author":"Bhatti","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e6525","DOI":"10.1097\/MD.0000000000006525","article-title":"The effectiveness and safety of angiotensin-converting enzyme inhibition or receptor blockade in vascular diseases in patients with hemodialysis","volume":"96","author":"Liao","year":"2017","journal-title":"Medicine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.ajkd.2008.04.031","article-title":"Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: An open-label randomized controlled trial","volume":"52","author":"Suzuki","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Liu, Y., Ma, X., Zheng, J., Jia, J., and Yan, T. (2017). Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: A meta-analysis of randomised controlled trials. BMC Nephrol., 18.","DOI":"10.1186\/s12882-017-0605-7"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","article-title":"2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: An update of the 2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America","volume":"68","author":"Yancy","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1002\/ehf2.15337","article-title":"Improvements in medical therapy and prognosis for patients with HFrEF following the 2021 ESC HF guidelines","volume":"12","author":"Berge","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ejhf.799","article-title":"Neprilysin inhibition in heart failure: Mechanisms and substrates beyond modulating natriuretic peptides","volume":"19","author":"Iacovoni","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","article-title":"Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: Rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)","volume":"15","author":"McMurray","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Mantegazza, V., Volpato, V., Mapelli, M., Sassi, V., Salvioni, E., Mattavelli, I., Tamborini, G., Agostoni, P., and Pepi, M. (2021). Cardiac Reverse Remodelling by 2D and 3D Echocardiography in Heart Failure Patients Treated with Sacubitril\/Valsartan. Diagnostics, 11.","DOI":"10.3390\/diagnostics11101845"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jchf.2020.06.020","article-title":"Sacubitril\/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF","volume":"8","author":"Docherty","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41540-017-0013-4","article-title":"Mechanisms of action of sacubitril\/valsartan on cardiac remodeling: A systems biology approach","volume":"3","author":"Roura","year":"2017","journal-title":"npj Syst. Biol. Appl."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis treatment of acute chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Lubl\u00f3y, \u00c1. (2014). Factors affecting the uptake of new medicines: A systematic literature review. BMC Health Serv. Res., 14.","DOI":"10.1186\/1472-6963-14-469"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00000441-200304000-00004","article-title":"Congestive heart failure in patients with chronic kidney disease and on dialysis","volume":"325","author":"Schreiber","year":"2003","journal-title":"Am. J. Med. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ekir.2023.10.008","article-title":"Systematic Review of Cardiovascular Benefits and Safety of Sacubitril-Valsartan in End-Stage Kidney Disease","volume":"9","author":"Charkviani","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e026407","DOI":"10.1161\/JAHA.122.026407","article-title":"Sacubitril\/Valsartan in Patients with Heart Failure and Concomitant End-Stage Kidney Disease","volume":"11","author":"Niu","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_20","first-page":"3439","article-title":"Effects and safety of Sacubitril\/Valsartan (SV) on heart function and blood pressure in maintenance hemodialysis (MHD) patients","volume":"14","author":"Wen","year":"2022","journal-title":"Am. J. Transl. Res."},{"key":"ref_21","first-page":"288","article-title":"Use of Angiotensin Receptor Neprilysin Inhibitor in Patients on Maintenance Hemodialysis with Reduced Cardiac Ejection Fraction, Real-World Experience from a Single Center","volume":"15","author":"Wang","year":"2021","journal-title":"Iran. J. Kidney Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/ejhf.3454","article-title":"Efficacy and safety of angiotensin receptor-neprilysin inhibition in heart failure patients with end-stage kidney disease on maintenance dialysis: A systematic review and meta-analysis","volume":"27","author":"Nguyen","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_23","first-page":"e63360","article-title":"Sacubitril\/Valsartan Improves Cardiac Function in Dialysis Patients","volume":"16","author":"Armaly","year":"2024","journal-title":"Cureus"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Guo, Y., Ren, M., Wang, T., Wang, Y., Pu, T., Li, X., Yu, L., Wang, L., Liu, P., and Tang, L. (2022). Effects of sacubitril\/valsartan in ESRD patients undergoing hemodialysis with HFpEF. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.955780"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zhao, C., Guo, Y., Wang, Y., Wang, L., Yu, L., Liang, Y., Zhai, Z., and Tang, L. (2022). The efficacy and safety of Sacubitril\/Valsartan on pulmonary hypertension in hemodialysis patients. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1055330"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/ehf2.14344","article-title":"Dramatic disease regression in a case of HFrEF with end-stage renal failure treated with sacubitril\/valsartan and SGLT2i","volume":"10","author":"Mapelli","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2222841","DOI":"10.1080\/0886022X.2023.2222841","article-title":"Effects of sacubitril-valsartan in patients undergoing maintenance dialysis","volume":"45","author":"Ding","year":"2023","journal-title":"Ren. Fail."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/clc.24075","article-title":"Effects of sacubitril-valsartan in the treatment of chronic heart failure patients with end-stage renal disease undergoing dialysis","volume":"46","author":"Liu","year":"2023","journal-title":"Clin. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Pascual-Figal, D., Bay\u00e9s-Genis, A., Beltr\u00e1n-Troncoso, P., Caravaca-P\u00e9rez, P., Conde-Martel, A., Crespo-Leiro, M.G., Delgado, J.F., D\u00edez, J., Formiga, F., and Manito, N. (2021). Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure with Reduced Ejection Fraction. A Review. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.754499"}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/9\/3\/291\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:10:52Z","timestamp":1789992652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/9\/3\/291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["reports9030291"],"URL":"https:\/\/doi.org\/10.3390\/reports9030291","relation":{},"ISSN":["2571-841X"],"issn-type":[{"value":"2571-841X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}